TY - JOUR T1 - Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 34 LP - 34 DO - 10.1136/dtb.2019.000081 VL - 58 IS - 3 AU - David Erskine Y1 - 2020/03/01 UR - http://dtb.bmj.com/content/58/3/34.abstract N2 - Early in 2019, the European Medicines Agency (EMA) extended the licence for dapagliflozin 5 mg tablets to include use by people with type 1 diabetes who have a body mass index (BMI) ≥27 kg/m2 when insulin alone does not provide adequate glycaemic control.1 The National Institute of Health and Care Excellence (NICE) subsequently adjudged dapagliflozin to be a cost-effective option for those with type 1 diabetes who require insulin doses of at least 0.5 units/kg of body weight per day.2 Additional requirements from NICE include the need for a structured education programme about diabetic ketoacidosis (DKA), to have treatment started and supervised by a specialist consultant physician and to stop the drug after 6 months if there is not a sustained improvement in glycaemic control.EMA authorisation for type 1 diabetes was based on two placebo-controlled trials … ER -